A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions
出版年份 2016 全文链接
标题
A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions
作者
关键词
Clopidogrel, Carbamazepine, Economic Evaluation, Prasugrel, Abacavir
出版物
PHARMACOECONOMICS
Volume 34, Issue 8, Pages 771-793
出版商
Springer Nature
发表日期
2016-03-19
DOI
10.1007/s40273-016-0397-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.
- (2016) Solen Pichereau et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Cost-effectiveness of screening forHLA-A*31:01prior to initiation of carbamazepine in epilepsy
- (2015) Catrin O. Plumpton et al. EPILEPSIA
- Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription
- (2015) Ritika Kapoor et al. Pharmacogenetics and Genomics
- Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea
- (2015) Dong-Jin Park et al. ARTHRITIS CARE & RESEARCH
- Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions
- (2014) Munir Pirmohamed Annual Review of Genomics and Human Genetics
- Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
- (2014) V. L. M. Yip et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review
- (2014) Sarah Cargnin et al. PHARMACOGENOMICS
- Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population
- (2014) Surasak Saokaew et al. PLoS One
- The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine
- (2014) Alexander J. Thompson et al. VALUE IN HEALTH
- Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
- (2013) Mark H. Eckman ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
- (2013) Waranya Rattanavipapong et al. EPILEPSIA
- A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
- (2013) Stephen E. Kimmel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Genotype-Guided Dosing of Warfarin
- (2013) Munir Pirmohamed et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost–effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
- (2013) Talitha I Verhoef et al. PHARMACOGENOMICS
- Cost–effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia
- (2013) Michael J Sorich et al. PHARMACOGENOMICS
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand
- (2013) Somsak Tiamkao et al. International Journal of Clinical Pharmacy
- Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
- (2012) A. LALA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
- (2012) Jason D Roberts et al. LANCET
- Pharmacogenetic tests: the need for a level playing field
- (2012) Munir Pirmohamed et al. NATURE REVIEWS DRUG DISCOVERY
- Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore
- (2012) D. Dong et al. NEUROLOGY
- The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
- (2012) Laura Panattoni et al. PHARMACOECONOMICS
- Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel
- (2012) Emily S. Reese et al. PHARMACOTHERAPY
- Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
- (2012) Joyce H. S. You et al. PLoS One
- A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia
- (2011) Jennifer R. Donnan et al. PEDIATRIC BLOOD & CANCER
- A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study
- (2011) William G Newman et al. PHARMACOGENOMICS
- Economic impact of a genetic test for cisplatin-induced ototoxicity
- (2011) F Dionne et al. PHARMACOGENOMICS JOURNAL
- Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries
- (2011) Paolo Olgiati et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain
- (2010) Diana Nieves Calatrava et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis
- (2010) Jared T. Hagaman et al. LUNG
- Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
- (2010) Teresa L. Kauf et al. PHARMACOECONOMICS
- Cost Effectiveness of Pharmacogenomics
- (2010) William B. Wong et al. PHARMACOECONOMICS
- Cost–effectiveness analysis in pharmacogenomics
- (2010) Katherine Payne et al. PHARMACOGENOMICS
- Systematic review of pharmacoeconomic studies of pharmacogenomic tests
- (2010) Mathieu Beaulieu et al. PHARMACOGENOMICS
- A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives
- (2010) Talitha I Verhoef et al. PHARMACOGENOMICS
- Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation
- (2009) Julio A. Leey et al. American Journal Geriatric Pharmacotherapy
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
- (2009) Heather Taffet Gold et al. CANCER
- Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
- (2009) Amanda R. Patrick et al.
- Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
- (2009) J H S You et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
- (2009) Lisa M. Meckley et al. PHARMACOECONOMICS
- Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
- (2009) Emma C. Davies et al. PLoS One
- The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV
- (2008) Bruce R Schackman et al. AIDS
- Avoiding adverse drug reactions by pharmacogenetic testing: A systematic review of the economic evidence in the case of TPMT and AZA-induced side effects
- (2008) Amelia Compagni et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- HLA-B*5701 Screening for Hypersensitivity to Abacavir
- (2008) Simon Mallal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin
- (2008) Andrew McWilliam et al. Personalized Medicine
- Cost–effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
- (2008) Marko Obradovic et al. PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now